RETIC Trial: Reversal of Trauma Induced Coagulopathy Using Coagulation

Status Terminated

Clinical Trial Summary

Severe traumatized patients (ISS > 15) admitted to emergency department (ED) University Hospital Innsbruck with obvious bleeding and/or who are at risk for significant hemorrhage will be screened by rotational thrombelastometry (ROTEM) assays during ED treatment and subsequent surgical/radiological interventions for having coagulopathy (T0). If a patient meets the inclusion criteria (T1) and is recruited for the study, a first study related blood sample (40mL) will be drawn, and data collected. Subsequently, 100 patients will be randomized to receive Fibrinogen concentrate and/or Prothrombin complex concentrate and/or FXIII concentrate for reversal of coagulopathy, while the other 100 patients will receive fresh frozen plasma (FFP),respectively.

Treatment failure will be registered if bleeding persists and ROTEM parameters do not improve after two times dosages of study drug. In these cases haemostatic rescue therapy will be administered. CFC (fibrinogen concentrate and/or PCC, and/or FXIII concentrate) will be administered to patients randomized to receive FFP and FFP will be administered to patients of the CFC group.

In cases unresponsive to comprehensive treatment or normal ROTEM combined with diffuse bleeding, other haemostatic medications can be administered (e.g rFVIIa, DDAVP, VWF/FVIII concentrate) as judged by the anesthetist in charge. The need and type of any rescue therapy will be documented and a ROTEM will be performed thereafter.

At admission to ICU (T0 ICU), 24h (T24 ICU) and 48h(T48 ICU) thereafter further study related blood samples are drawn (40mL each).

The indications for transfusion of red blood cells or platelets, administration of antifibrinolytics, treatment of acidosis, hypothermia, hypocalcemia and volume replacement are similar for both groups and treatment is performed according to clinical routine.

Besides coagulation management during ED treatment until 24h on ICU, patient's care is not influenced by the study and follows clinical routine.

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01545635
Study type	Interventional
Source	Medical University Innsbruck
Contact
Status	Terminated
Phase	Phase 3
Start date	March 2012
Completion date	February 2016

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT02509390` - Hyperfibrinogenemia After Major Trauma	N/A
Recruiting	`NCT04970433` - The Effects of Acupuncture for Major Trauma	N/A
Recruiting	`NCT04588311` - ErythroPOietin Alfa to Prevent Mortality and Reduce Severe Disability in Critically Ill TRAUMA Patients	Phase 3
Active, not recruiting	`NCT04144803` - Brain Oxygenation During Prehospital Anesthesia: an Observational Study
Completed	`NCT03259776` - Experiences of Visitors to a Regional Major Trauma Intensive Care Unit
Recruiting	`NCT05449522` - Vitamin D for Critically Traumatic Patients	N/A
Not yet recruiting	`NCT06103292` - Calcium Levels in Major Trauma
Recruiting	`NCT02877342` - Pre-hospital Notification of Injured Patients Presenting to Trauma Centres in India	N/A
Completed	`NCT03986736` - Markers of Tissue Injury and Rhabdomyolysis in Patients With Major Trauma
Completed	`NCT03005509` - Structured Trauma Quality Improvement Meetings at Four Trauma Centres in India	N/A
Completed	`NCT02165137` - Management of Major Trauma Patients at Aarau Trauma Center - Evaluation of Processes and Patient Outcome
Active, not recruiting	`NCT06376318` - Shock and Acute Conditions OutcOmes Platform
Recruiting	`NCT05996068` - Arterial Line in Trauma Resuscitation	N/A
Completed	`NCT06007807` - Severe Trauma Registry in Tarragona
Completed	`NCT03354559` - Trauma Associated Bleeding: Effectiveness of an Early Coagulation Support Protocol	N/A
Recruiting	`NCT05652790` - Enhanced Rehabilitation After Major Trauma (PROPERLY)	N/A
Completed	`NCT00588796` - Study of Fibrinogen Metabolism During Severe Trauma and Burns	N/A
Completed	`NCT04216459` - Effect of Anti-inflammatory and Anti-microbial Co-supplementations in Traumatic ICU Patients at High Risk of Sepsis	N/A
Terminated	`NCT04551157` - Impact of Psychoeducational Video on Adjustment to Open Fracture.	N/A
Completed	`NCT02000674` - Succinylcholine vs Rocuronium for Prehospital Emergency Intubation	Phase 3

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

RETIC Trial: Reversal of Trauma Induced Coagulopathy Using Coagulation Factor Concentrates or Fresh Frozen Plasma

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms